Brain tumours in children: Hereditary genetic defect destabilises protein regulation

Google+ Pinterest LinkedIn Tumblr +

The causes of 40 percent of all cases of certain medulloblastoma – dangerous brain tumours affecting children – are hereditary.

These are the findings of a recent genetic analysis carried out by scientists from the Hopp Children’s Cancer Center (KiTZ), Germany, the European Molecular Biology Laboratory (EMBL) and numerous colleagues around the world, which have just been published in the scientific journal Nature.

A genetic defect that occurs in 15 percent of these children plays a key role by destabilising the production and breakdown of proteins.

The researchers suspect that protein metabolism defects could be a previously underestimated cause of other types of cancer.

The “Hopp Children’s Cancer Center Heidelberg” (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and Heidelberg University.

Medulloblastoma are among the most common malignant brain tumours affecting children.

They spread from the cerebellum to the surrounding tissue and can also spread to other parts of the central nervous system via the cerebrospinal fluid.

Because these tumours grow rapidly, physicians do not have much time to find a suitable treatment.

Physicians at the Hopp Children’s Cancer Center (KiTZ) specialise in characterising the molecular properties of children’s cancers in order to be able to recommend other treatment options besides standard therapies, and to develop new therapies with a focus on the mode of action.

Together with colleagues from EMBL, the German Cancer Consortium (DKTK) and the St. Jude Children’s Research Hospital in Memphis, USA, the KiTZ researchers conducted the most comprehensive medulloblastoma-related genetic investigation to date.

They analysed the genome and tumour genome of 800 children, young people and adults with medulloblastoma and compared the genetic data with data from healthy individuals.

In doing so, they came across a particularly striking hereditary difference in children and young people with brain tumours in the Sonic Hedgehog medulloblastoma subgroup.

A hereditary genetic defect in 15 percent of cases meant that patients were no longer able to produce the elongator complex protein 1 (ELP1) in the tumour.

The elongator complex protein is involved in ensuring that proteins are properly assembled and folded in line with the genetic code.

The latest findings show that, without ELP1, much of the protein metabolism is disturbed: “The assembly and folding of larger proteins in particular does not function properly any more, and the accumulation of these non-functioning or malfunctioning proteins places the cells under permanent stress,” says KiTZ Director Stefan Pfister, who is a head of department at the DKFZ and an expert in targeted therapies within the DKTK.

“Hundreds of proteins are misregulated in this way, including proteins that are important for nerve cell development.”

By analysing the genome of some parents and grandparents, the researchers also established that the cancer-activating ELP1 genetic defect is hereditary.

“That makes this the most common congenital genetic defect associated with medulloblastoma to date”, says Jan Korbel, a co-author of the study who works at EMBL.

Lead author Sebastian Waszak adds: “The latest results show that around 40 percent of children and young people who suffer from this subtype of medulloblastoma have a congenital genetic predisposition for it. That is a much higher proportion than we had assumed.”

Identifying hereditary causes of cancer in advance can help to make the right therapeutic decision and reduce the risk of relapse in children.

“For example, in the case of a hereditary predisposition for DNA breaks, certain chemotherapies or radiotherapy can lead to secondary tumours. In such cases, the first disease should not be treated too aggressively,” says Stefan Pfister.

Source: German Cancer Research Center


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.